Loading Events

Kazia Therapeutics Virtual Event: Advancing a New Frontier in Oncology with a First-in-Class Nuclear PD-L1 Protein Degrader

Events Banners_2 (33)
DATE: December 2, 2026
TIME: 4:00 PM EST
LOCATION: Virtual

About The Event

Join Kazia Therapeutics for a virtual event featuring management’s overview of NDL2, the Company’s novel nuclear PD-L1 protein degrader designed to address mechanisms of immunotherapy resistance in advanced solid tumors, with an initial focus on metastatic breast cancer and colorectal cancer. NDL2 represents a potentially first-in-class approach within the emerging field of targeted protein degradation, a therapeutic category with no known nuclear PD-L1 protein degraders currently in clinical development.

The event will explore the scientific discovery of NDL2 from initial concept through molecular optimization and pre-IND development, highlighting its potential to advance a differentiated approach to cancer immunotherapy. NDL2 is an optimized bicyclic peptide designed to selectively degrade disease-associated nuclear PD-L1 protein, with the goal of restoring the body’s natural anti-tumor immune response. While PD-L1 plays an important role in regulating the immune system, cancer cells can exploit this pathway to evade immune detection and resist treatment. Through targeted protein degradation (TPD), Kazia is pursuing an approach designed to harness the body’s natural protein degradation machinery to target disease-associated proteins, with the potential to overcome limitations of conventional immunotherapies.

A live question and answer session will follow the formal presentations.

Disclaimer: NDL2 is an investigational, preclinical-stage therapeutic candidate and has not been approved for clinical use. Statements regarding its potential therapeutic benefits and future development are forward-looking and subject to risks and uncertainties. Additional information regarding these risks is available in Kazia Therapeutics’ filings with the U.S. Securities and Exchange Commission.